Company Filing History:
Years Active: 1988-2025
Title: The Innovative Contributions of Ronald E Steele
Introduction
Ronald E Steele is a notable inventor based in Long Valley, NJ (US). He has made significant contributions to the field of pharmaceuticals, holding a total of 9 patents. His work primarily focuses on compounds that address health issues related to aldosterone overexposure.
Latest Patents
One of his latest patents is for an aldosterone synthase inhibitor. This invention relates to a compound selected from (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and its pharmaceutically acceptable salts, particularly the phosphate salt of the compound. The invention emphasizes the importance of having an enantiomeric excess of the (R) form higher than or equal to 97%. It also discusses pharmaceutical compositions that utilize this compound for treating diseases and disorders in humans, including women of childbearing potential and pediatric patients, where aldosterone overexposure is a contributing factor.
Another significant patent involves R-fadrozole for the treatment of aldosteronism. This composition is designed for diseases or disorders where aldosterone overexposure contributes to symptoms. The composition includes (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine or its pharmaceutically acceptable salts, with a focus on daily administration to subjects in need.
Career Highlights
Throughout his career, Ronald E Steele has worked with prominent companies such as Ciba-Geigy Corporation and Damian Pharma AG. His experience in these organizations has contributed to his expertise in pharmaceutical innovations.
Collaborations
Ronald has collaborated with notable individuals in his field, including Robert M Bowman and Leslie J Browne. These partnerships have likely enhanced his research and development efforts.
Conclusion
Ronald E Steele's innovative work in pharmaceuticals, particularly concerning aldosterone-related treatments, showcases his significant contributions to medical science. His patents reflect a commitment to improving health outcomes through targeted pharmaceutical solutions.